The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 - Wikidata - awgldk - TriplyDB

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

http://www.wikidata.org/entity/Q27491317

about

Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host Development, characterization and application of monoclonal antibodies against Brazilian Dengue virus isolates Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections An in-depth analysis of original antigenic sin in dengue virus infection Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus Recent advances in understanding dengue Vaccine-mediated immunity against dengue and the potential for long-term protection against disease Intra-epidemic evolutionary dynamics of a Dengue virus type 1 population reveal mutant spectra that correlate with disease transmission.Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity The structural basis for serotype-specific neutralization of dengue virus by a human antibody A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies.Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.Passive immune neutralization strategies for prevention and control of influenza A infections.Extensive structural change of the envelope protein of dengue virus induced by a tuned ionic strength: conformational and energetic analyses.Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells.Molecular characterization and genotype shift of dengue virus strains between 2001 and 2014 in Guangzhou Endemic dengue associated with the co-circulation of multiple viral lineages and localized density-dependent transmission In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.Progress in the identification of dengue virus entry/fusion inhibitors Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines.Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay Dengue.Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries.Development of a humanized antibody with high therapeutic potential against dengue virus type 2 Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes.The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.Highly efficient selection of epitope specific antibody through competitive yeast display library sorting Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.

P2860

Q23925011-A0488E9A-C884-4FE7-804D-F66388C3FAF2 Q24288673-2C23DAEF-0935-4029-9CDF-48BA50DBF9AF Q24289014-E776BDE0-B83A-4A72-8EAB-05A4BDD9ABC0 Q24606493-07B5E8DE-5700-42BE-9E89-CE952DB4102C Q26252060-FCE0C2D2-0970-4364-89D3-DCF245C82284 Q26314715-F5FD7902-0A9D-4AEC-B20A-05E450C3CFFA Q26700001-BEC375CC-79DE-4A44-A0A0-330173A2A31B Q26766156-F2A8CEF9-A735-4A9B-A627-252F7768DBE4 Q27014663-64159C30-A4E0-4C34-88FB-2C0481FB6569 Q27334417-805151A7-D4ED-429D-9697-3C83F00F3335 Q27654848-28B16995-E6F6-4C82-82D0-498AFE4FAE71 Q27674417-E3FAEBA7-D894-48A8-93CB-BC147E1B29B8 Q27675965-14E4372D-38A2-44CC-9144-5B917A5D4F3F Q27678419-D8C9C6D5-EB6A-4B87-8F92-73F7165F447B Q27681306-01A6CC59-2CDB-4BA1-BD41-721D45168479 Q27681319-2F118A97-9D2F-421C-8333-83D9DBDAD5D7 Q29994510-EC7ACC65-71CA-4ACB-92B7-670B0C24E0B5 Q30145645-5623AAA4-5170-4DF2-B286-C1F7FE886E3F Q30395028-D7E46E02-C352-4E65-8D9F-1260A28A5944 Q30413158-94CF181F-8CB1-4354-9C63-01DE6620F843 Q30423742-223AC0BF-DFA8-4300-8D9F-4612DBE97EAD Q33425879-D6F599E0-DD69-49C4-A818-C41B66E84C2A Q33431345-CE2472DF-B80B-4FA7-8D5D-84695EB325D4 Q33661999-DF11134D-9516-453D-B06B-0732AC3F94C0 Q33926902-69F86656-57DC-4E71-8CF8-612B2449A071 Q33945441-94376FB3-1C8C-4D1E-810C-DFF1FDF4C045 Q33954392-BB9B7D4B-7837-445F-BD6E-7BF1D3598162 Q33968024-AADC2DBC-B779-4CC7-9955-435621697EE4 Q34054616-1C4EC7EF-B9EB-40A3-8DC9-26E49F64AD0B Q34059579-CBF5DE24-1A07-4C2C-BEA2-D46DD1ABAAD1 Q34120070-DD398685-0C2D-4448-BF6F-9ED846F23D0E Q34123956-6097F091-43B9-41EA-AC69-9120A243584C Q34125057-71DEA62B-544E-417E-BF1D-7120A728B562 Q34226542-33402136-6744-45CE-8471-ECC321DBE002 Q34260219-E427D335-ADE8-4F1C-B899-F8E49523FEA1 Q34262245-10ACD87F-2338-4700-AAC6-6C6C9FF5B386 Q34470605-58683043-851F-42C4-83B9-577AAF79AC99 Q34614953-E86D6FC6-04C4-4B16-A606-EBD476A578DD Q34772027-65EC8E7E-EDEA-4579-9305-04C808F0FF48 Q34779065-453A1A7E-250B-4932-B023-BB540FF146BD

P2860

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

http://www.wikidata.org/entity/Q27491317

description

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

article scientifique (publié 2010/04/01)

@fr

articolo scientifico (pubblicato il 2010/04/01)

@it

artigo científico (publicado na 2010/04/01)

@pt

artículu científicu espublizáu en 2010

@ast

im April 2010 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: April 2010)

@en

vedecký článok (publikovaný 2010/04/01)

@sk

videnskabelig artikel (udgivet 2010/04/01)

@da

name

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@ast

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@en

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@nl

type

label

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@ast

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@en

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@nl

prefLabel

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@ast

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@en

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@nl

P1433

Q27491317-541FEB58-0E2F-4B01-9888-4AB790EDAB3D

P1476

Q27491317-9AD1AF45-11A3-45D2-9E9A-0AB8F4C72581

P2093

Q27491317-00AB197F-DEFB-41CB-8816-E346D56BA87D

Q27491317-159E2C09-8E04-4C58-BCDB-98FC592F581C

Q27491317-3BEE46EB-E097-45EA-9A12-BFCF96C59A93

Q27491317-66949ED4-7656-4FB3-8594-0225C9752B1D

Q27491317-716C78E0-DA0B-468A-8428-3B3896A00C7F

Q27491317-73634B88-A09C-438F-A156-71681C4FFA14

Q27491317-C117E7A8-151D-465B-B006-99D16C66F5A9

Q27491317-E98EBCC9-A695-486A-996D-84B91FFCF2E5

P2860

Q27491317-00D7A923-2643-4C78-90AC-196039495668

Q27491317-019C4A78-4781-4DAB-8698-A4E6315117E2

Q27491317-0271DCB2-BBB5-48EC-97AC-34B71343E919

Q27491317-03DBE466-FE6B-41F6-A2D5-AD4E6576A724

Q27491317-04D68E8E-B884-4657-8D2C-13ED4AED8ED4

Q27491317-0A143B2D-F84B-43EF-8628-0E952A40F2C9

Q27491317-10F362F2-83B3-44E6-95F1-2EA6951ECC4E

Q27491317-11B2FEE4-5ABB-4DF3-A8AC-75004E944D18

Q27491317-12CEDAE5-97E4-4466-BD4A-745CAE62C7E5

Q27491317-14F90B36-9528-4779-A6C8-665D2880CB34

P304

Q27491317-1B520312-B67D-429A-8616-F30E8DC92FCB

P31

Q27491317-F06AC5AA-E721-4BC9-9890-CCB564A176F6

P3181

Q27491317-926BBD66-B96D-49D6-8CEE-B9217AB1C374

P356

Q27491317-14CB4C40-E0AC-444F-9A2C-8A02D2C6134C

P433

Q27491317-9E69D38E-8242-4140-8441-C42857FA0CC1

P478

Q27491317-374DA745-99D4-4D81-83B4-5D6ABF594F74

P50

Q27491317-1E967C2A-9223-4A0E-9222-C6C0E2518C62

Q27491317-8D1AEF1E-92D9-471C-BC4D-6011B3193CEE

Q27491317-9422AAC4-22DA-4CB2-B6D5-08C68B3D22DB

P5008

Q27491317-CA2053CB-382D-4733-B8F4-9526D5A371E7

P577

Q27491317-1C34A4E1-0DA6-4525-8967-850DC9B57A04

P5875

Q27491317-26228F6D-7165-4196-ABD3-33963E551022

P698

Q27491317-B79AFFE4-77AA-4A7E-A435-BD5BFAFAE26C

P921

Q27491317-45A773B6-2034-4942-9005-F8C1C7B3FAFB

Q27491317-4AA39E31-4DC6-4700-80F8-C84D6B868C8C

P932

Q27491317-D2E46BA1-3ABE-4A23-BE59-02AF50EFF4D9

P3181

P356

JOURNAL.PPAT.1000823

P1433

P1476

The Development of Therapeutic ...... notypes of Dengue Virus Type 1

@en

P2093

Christopher A Nelson

http://www.w3.org/2001/XMLSchema#string

Daved H Fremont

http://www.w3.org/2001/XMLSchema#string

James D Brien

http://www.w3.org/2001/XMLSchema#string

Katie M O'Brien

http://www.w3.org/2001/XMLSchema#string

Melissa A Edeling

http://www.w3.org/2001/XMLSchema#string

S Kyle Austin

http://www.w3.org/2001/XMLSchema#string

Syd Johnson

http://www.w3.org/2001/XMLSchema#string

Taekyung Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes

Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses

Flavivirus genome organization, expression, and replication

DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells

Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification

New mouse model for dengue virus vaccine testing

Dengue virus structural differences that correlate with pathogenesis.

Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein

P304

e1000823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

793988

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PPAT.1000823

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Michael S. Diamond

Soila Sukupolvi-Petty

P5008

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43023971

http://www.w3.org/2001/XMLSchema#string

P698

20369024

http://www.w3.org/2001/XMLSchema#string

P921

P932

2848552

http://www.w3.org/2001/XMLSchema#string